Cardiac Metastasis of Hepatocellular Carcinoma Mimicking Pericardial Effusion on Radionuclide Angiocardiography

CHEST Journal ◽  
1992 ◽  
Vol 101 (1) ◽  
pp. 261-262 ◽  
Author(s):  
Kou-Gi Shyu ◽  
Fu-Tien Chiang ◽  
Peiliang Kuan ◽  
Wen-Pin Lien ◽  
Chi-Long Chen ◽  
...  
F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 1243
Author(s):  
Andrianto Andrianto ◽  
Eka Prasetya Budi Mulia ◽  
Denny Suwanto ◽  
Dita Aulia Rachmi ◽  
Mohammad Yogiarto

Metastatic tumors of the heart presenting with complete heart block (CHB) is an extremely uncommon case. There are no available guidelines in managing CHB in terminal cancer. Permanent pacemaker implantation in such cases is a challenge in terms of clinical utility and palliative care. We report a case of a 24-year-old man suffering from tongue cancer presenting with CHB. An intracardiac mass and moderate pericardial effusion were present, presumed as the metastatic tumor of tongue cancer. We implanted a temporary pacemaker for his symptomatic heart block and cardiogenic shock, and pericardiocentesis for his massive pericardial effusion. We decided that a permanent pacemaker would not be implanted based on the low survival rate and significant comorbidities. Multiple studies report a variable number of cardiac metastasis incidence ranging from 2.3% to 18.3%. It is rare for such malignancies to present with CHB. The decision to implant a permanent pacemaker is highly specific based on the risks and benefits of each patient. It needs to be tailored to the patient’s functional status, comorbid diseases, prognosis, and response to conservative management.


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 10060-10060
Author(s):  
D. P. Hughes ◽  
M. Crutchley ◽  
W. I. Douglas ◽  
M. F. Munsell ◽  
A. A. Vaporciyan ◽  
...  

10060 Background: Sarcoma metastasizing to the heart is a difficult and complicated clinical problem, yet local control is feasible and effective for select patients with cardiac metastasis. Diligence is required to detect these lesions while still amenable to treatment, and echocardiogram remains the best tool for detecting cardiac disease. Methods: We reviewed all echocardiograms (1330) performed on 307 pediatric sarcoma patients treated at UT M. D. Anderson Cancer Center between 1997 and 2008. Measures of cardiac function and pathology (including size of ventricles and atria, function of ventricles and valves, presence of metastasis, and presence of pericardial effusion) were assigned numerical values. Fisher's exact test and the Wilcoxon rank-sum test compared clinical characteristics of patients with and without cardiac metastases. Results: The prevalence of cardiac metastases was 1.6% (5/307) with 95% confidence interval 0.5% to 3.8%. The presence of cardiac metastasis positively correlated with pericardial effusion (p = 0.001) and tricuspid valve insufficiency (p = 0.014). The probability of a patient with pericardial effusion having a cardiac metastasis was 28.6% (95% CI: 3.7%-71%). Of the 5 patients with documented sarcoma metastasis to the heart, 3 had widespread refractory disease, were given no cardiac-specific therapy, and rapidly died from disease. One patient who had widespread disease controlled with chemotherapy and radiation had open resection of 2 cardiac metastases which resulted in site-specific disease control for 6 months before succumbing to progressive extra-cardiac disease. Another patient had isolated cardiac metastasis, treated with open resection of 2 metastases followed by adjuvant chemotherapy, and has been without recurrent cardiac metastases for 5 years and 9 months. Conclusions: Durable local control for sarcoma metastasizing to the heart is possible and effective for select patients. Pericardial effusion merits evaluation for potential associated cardiac metastasis. Echocardiogram monitoring of sarcoma patients remains important, and should include screening for possible cardiac metastasis. No significant financial relationships to disclose.


2010 ◽  
Vol 25 (1) ◽  
pp. 150-155 ◽  
Author(s):  
Yu-Chun Liu ◽  
Yi-Lwun Ho ◽  
Guan-Tarn Huang ◽  
Ding-Shinn Chen ◽  
Jin-Chuan Sheu ◽  
...  

2020 ◽  
Vol 5 (2) ◽  

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver and eighth-most common cancer. The most frequent sites of metastasis are the lungs, the bones, the lymphatics, and the brain. An isolated metastasis of a HCC to the right atrium and inferior vena cava (IVC) is extremely rare. Here we discuss a case of a 61-year-old female who presented with two weeks of generalized weakness and was found to have advanced stage HCC with metastasis to the IVC and right atrium of her heart. We recommend that echocardiography should be routinely performed for all patients with advanced HCC because if metastasis to the right atrium is not detected early enough, the clinical course will be complicated by many unexpected cardiovascular complications that can be fatal. Currently the prognosis for this disease is very poor so further investigation into surgical and medical treatments needs to occur.


2017 ◽  
Vol 11 (2) ◽  
pp. 416-421 ◽  
Author(s):  
Mashal Salehi ◽  
The Yee ◽  
Eric Alatevi ◽  
Yamin Thein

Intracavitary cardiac extension remains an unusual site of extrahepatic metastasis in patients with hepatocellular carcinoma. While patients can present with signs and symptoms suggestive of right-sided heart failure, it may be totally asymptomatic, which is very rare with only a few cases reported so far. Also, cardiac metastasis is of great prognostic importance as patients with intracardiac metastasis can have an extremely poor prognosis. Here, we present the case of a 52-year-old male patient with advanced hepatocellular carcinoma, with an incidentally found tumor thrombus extending from the inferior vena cava to the right atrium, protruding through the tricuspid valve into the right ventricle, on routine echocardiography. The patient did not have any signs or symptoms of heart involvement and unfortunately died on the 18th day of the hospital stay.


Sign in / Sign up

Export Citation Format

Share Document